Blog
RSS FeedPosted by Michael Wonder on 06 Nov 2017
Health Canada approves Otsuka and Lundbeck's Abilify Maintena (aripiprazole once Monthly) as treatment for bipolar I disorder in adults
2 November 2017 - Otsuka Canada and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for Abilify Maintena ...
Posted by Michael Wonder on 05 Nov 2017
Health Canada approves Actemra (tocilizumab) for Canadians living with giant cell arteritis
2 November 2017 - Actemra is the first non-steroid treatment designed to directly target the interleukin-6 (IL-6) receptor, offering a ...
Posted by Michael Wonder on 02 Nov 2017
Pediapharm receives Health Canada approval for Cuvposa
1 November 2017 - Pediapharm is very pleased to announce Health Canada's notice of compliance (approval) for Cuvposa (Glycopyrrolate oral ...
Posted by Michael Wonder on 31 Oct 2017
Janssen announces Imbruvica (ibrutinib) as the first approved treatment for chronic graft-versus-host disease granted by Health Canada priority review
30 October 2017 - Approval provides a much-needed option for patients who develop this life-threatening condition following stem cell transplant. ...
Posted by Michael Wonder on 17 Oct 2017
Health Canada gives 'kiss of death' to planned policy for rare-disease drugs
16 October 2017 - The framework was announced by the Harper government in 2012, but sat on the back burner since ...
Posted by Michael Wonder on 16 Oct 2017
GSK announces first approval of Shingrix in Canada
13 October 2017 - The only shingles vaccine to achieve ≥90% efficacy in adults aged 50 and over. ...
Posted by Michael Wonder on 28 Sep 2017
Stallergenes Greer advances its house dust mite allergy pipeline with acceptance of regulatory submission and new market approval
26 September 2017 - The company also received market approval to commercialise STG320 in New Zealand under the Actair brand name. ...
Posted by Michael Wonder on 25 Sep 2017
Gilead receives approval in Canada for expanded indication of Epclusa (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C in patients co-infected with HIV
21 September 2017 - New data for first approved pan-genotypic once-daily single tablet regimen for chronic hepatitis C virus infection. ...
Posted by Michael Wonder on 19 Sep 2017
Akcea announces filing of new drug submission for volanesorsen to Health Canada
12 September 2017 - Health Canada grants priority review for volanesorsen new drug submission filing. ...
Posted by Michael Wonder on 18 Sep 2017
Amicus Therapeutics announces approval for Galafold (migalastat) for treatment of Fabry disease in Canada
14 September 2017 - First oral precision medicine for Fabry disease with broad label for Fabry patients with amenable genetic ...
Posted by Michael Wonder on 29 Aug 2017
Health Canada approves Tresiba, a new basal insulin for type 1 and 2 diabetes
28 August 2017 - The new once-daily, ultra-long-acting insulin provides a glucose-lowering effect beyond 42 hours. ...
Posted by Michael Wonder on 21 Aug 2017
AbbVie’s Maviret approved by Health Canada for the treatment of chronic hepatitis C in all major genotypes
17 August 2017 - Maviret is the first and only 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who ...
Posted by Michael Wonder on 20 Aug 2017
Gilead receives approval in Canada for Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for re-treatment of certain patients with chronic hepatitis C virus infection
17 August 2017 - VOSEVI is the first once daily, single tablet hepatitis C virus (HCV) regimen for re-treatment, and ...
Posted by Michael Wonder on 16 Aug 2017
Health Canada approves Ocrevus (ocrelizumab) for Canadians living with relapsing-remitting multiple sclerosis
15 August 2017 - Ocrevus is a first-in-class treatment that targets B-cells, offering a new pathway to treat multiple sclerosis. ...
Posted by Michael Wonder on 14 Aug 2017
Onivyde (irinotecan liposome for injection) has received approval in Canada for the treatment of metastatic adenocarcinoma of the pancreas in the post-gemcitabine setting
11 August 2017 - Onivyde, in combination with 5-fluorouracil and leucovorin, is the first and only treatment shown to increase ...